Ireland
--:--IST
Starting soon Observational

Turkish Validity and Reliability of the Parkinson's Disease Neuropsychometric Dementia Assessment Questionnaire in Individuals With Parkinson's Disease

NCT07815964 · tracked via the Priya Life Science Turkey tracker
Phase
Observational
Started
2026-10-01
Last updated
2026-09-14

Condition(s) studied

PARKINSON DISEASE (Disorder)

Investigational drug(s) / intervention(s)

Parkinson Neuropsychometric Dementia Assessment

Parkinson Neuropsychometric Dementia Assessment: Participants will complete the Turkish version of the Parkinson Neuropsychometric Dementia Assessment (PANDA) as part of the psychometric evaluation process. The PANDA will be administered according to standardized instructions to assess cognitive performance in individuals with Parkinson's disease. To evaluate test-retest reliability, the Turkish PANDA will be re-administered to a subgroup of participants after a predefined interval under similar conditions. No therapeutic intervention will be provided as part of this methodological validation study.

Study summary

The aim of this study is to examine the validity and reliability of the Turkish version of the Parkinson's Neuropsychometric Dementia Assessment (PANDA) in individuals with Parkinson's disease. This cross-sectional methodological study will evaluate the psychometric properties of the Turkish PANDA, including internal consistency, test-retest reliability, and construct validity, in order to provide a valid and reliable instrument for the assessment of cognitive impairment and dementia-related cognitive changes in Turkish-speaking individuals with Parkinson's disease.

Eligibility

Sex
ALL
Min age
40 Years
Max age
—
Healthy volunteers
No
\*\*Inclusion Criteria:\*\* * Clinical diagnosis of Parkinson's disease * Hoehn and Yahr stage 1-3 * Age between 40 and 85 years * Mini-Mental State Examination score ≥ 24 * Sufficient cognitive and communication ability to complete the assessments * Attendance at the Movement Disorders Outpatient Clinic of the Neurology Department * Willingness to participate in the study and provide written informed consent \*\*Exclusion Criteria:\*\* * Presence of a major psychiatric disorder, such as major depressive disorder or a psychotic disorder * Diagnosis of advanced dementia * Presence of an uncontrolled systemic chronic disease, such as uncontrolled diabetes mellitus or hypertension * Presence of a severe cardiovascular or respiratory condition * Presence of an additional orthopedic or neurological condition that may affect assessment performance * Severe visual or hearing impairment that may interfere with the assessments * Inability to cooperate adequately during the assessments

Primary outcome measure(s)

  • Parkinson Neuropsychometric Dementia Assessment (PANDA) Total Score — [Time Frame: Baseline (at the time of PANDA administration)]
    Cognitive performance will be assessed using the Turkish version of the Parkinson's Neuropsychometric Dementia Assessment (PANDA) in individuals with Parkinson's disease. The PANDA is a brief cognitive screening instrument specifically developed for Parkinson's disease and includes tasks assessing learning and memory, verbal fluency, visuospatial processing, working memory, and delayed recall. The PANDA total score ranges from 0 to 30, with higher scores indicating better cognitive performance. The psychometric properties of the Turkish version, including internal consistency, test-retest reliability, and construct validity, will be evaluated.

Trial sites (1)

FacilityCityRegionStatus
Acibadem University Istanbul Turkey
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07815964 on ClinicalTrials.gov ↗ ← All trials in Turkey